Lupin, a multinational pharmaceutical company, completed the acquisition Medisol, a pharmaceutical company. Financial terms were not disclosed. “The acquisition of Medisol marks a significant milestone in Lupin’s journey to strengthen our injectables portfolio in France, the second-largest market in Europe for injectables. Medisol’s unique product portfolio complements our existing range, enabling us to offer our customers an even more robust selection of high-quality products. This acquisition underscores our unwavering commitment to expanding our presence in the EMEA region and providing superior healthcare to patients," Thierry Volle, Lupin President.